Preoperative transarterial chemoembolization does not improve the outcomes of resectable hepatocellular carcinoma: A propensity score-matched study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Transarterial chemoembolization (TACE) is reserved for the treatment of intermediate hepatocellular carcinoma (HCC) (Barcelona Clinic Liver Cancer stage B); however, it can also be utilized as a neoadjuvant treatment prior to surgical resection in resectable HCC cases. This study aimed to clarify the benefits of TACE in patients with resectable HCC. Methods: Data were retrospectively collected from patients with resectable HCC who had undergone hepatectomy between January 2010 and December 2015. A 1:1 propensity-matched case-control study was conducted using a logistic regression model that included the following covariates: sex, age, Model for end-stage liver disease score, and the number and size of tumors. Results: Of 160 patients, 37 and 123 were included in the TACE before liver resection (TACE-LR) and upfront LR groups, respectively. After 1:1 propensity score matching in the LR-matched group (n = 37), no significant differences in baseline parameters were found between the TACE-LR and LR-matched groups. Moreover, there were no significant differences in short-term outcomes, including intraoperative blood loss (800 mL vs. 500 mL, P = 0.148), operative time (300 min vs. 290 min, P = 0.824), and overall morbidity (24.3% vs. 13.51%, P = 0.235) between the TACE-LR and LRmatched groups. As long-term outcomes, no significant between-group differences were found in the 5-year disease-free survival rate (TACE-LR, 38%; LR, 58%; P = 0.89) or the 5-year overall survival rate (TACE-LR, 80.9%; LR, 80.8%; P = 0.72). Conclusion: The short- and long-term outcomes were not significantly different between preoperative TACE and LR for resectable HCC.
Abstract
Background: Transarterial chemoembolization (TACE) is reserved for the treatment of intermediate hepatocellular carcinoma (HCC) (Barcelona Clinic Liver Cancer stage B); however, it can also be utilized as a neoadjuvant treatment prior to surgical resection in resectable HCC cases. This study aimed to clarify the benefits of TACE in patients with resectable HCC. Methods: Data were retrospectively collected from patients with resectable HCC who had undergone hepatectomy between January 2010 and December 2015. A 1:1 propensity-matched case-control study was conducted using a logistic regression model that included the following covariates: sex, age, Model for end-stage liver disease score, and the number and size of tumors. Results: Of 160 patients, 37 and 123 were included in the TACE before liver resection (TACE-LR) and upfront LR groups, respectively. After 1:1 propensity score matching in the LR-matched group (n = 37), no significant differences in baseline parameters were found between the TACE-LR and LR-matched groups. Moreover, there were no significant differences in short-term outcomes, including intraoperative blood loss (800 mL vs. 500 mL, P = 0.148), operative time (300 min vs. 290 min, P = 0.824), and overall morbidity (24.3% vs. 13.51%, P = 0.235) between the TACE-LR and LRmatched groups. As long-term outcomes, no significant between-group differences were found in the 5-year disease-free survival rate (TACE-LR, 38%; LR, 58%; P = 0.89) or the 5-year overall survival rate (TACE-LR, 80.9%; LR, 80.8%; P = 0.72). Conclusion: The short- and long-term outcomes were not significantly different between preoperative TACE and LR for resectable HCC.
참고문헌 (45)
- Jemal A, "Annual report to the nation on the status of cancer, 1975-2014, featuring survival", J Natl Cancer Inst, 109, pp.djx030~ (2017)
- European Association for the study of the liver, "EASL Clinical Practice Guidelines:management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
- Omata M, "Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma : a 2017 update", Hepatol Int, 11, pp.317~370 (2017)
- Marrero JA, "Diagnosis, staging, and management of hepatocellular carcinoma : 2018 practice guidance by the American Association for the study of liver diseases", Hepatology, 68, pp.723~750 (2018)
- Reig M, "BCLC strategy for prognosis prediction and treatment recommendation : the 2022update", J Hepatol, 76, pp.681~693 (2022)
- Lencioni R, "Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy", Crit Rev Oncol Hematol, 83, pp.216~224 (2012)
- Lencioni R, "Chemoembolization of hepatocellular carcinoma", Semin Intervent Radiol, 30, pp.3~11 (2013)
- Raoul JL, "Updated use of TACE for hepatocellular carcinoma treatment : how and when to use it based on clinical evidence", Cancer Treat Rev, 72, pp.28~36 (2019)
- Makary MS, "Locoregional therapy approaches for hepatocellular carcinoma : recent advances and management strategies", Cancers(Basel), 12, pp.1914~ (2020)
- Kollmann D, "Bridging to liver transplantation in HCC patients", Langenbecks Arch Surg, 402, pp.863~871 (2017)
- Lubienski A, "Hepatocellular carcinoma : interventional bridging to liver transplantation", Transplantation, 80(1 Suppl), pp.S113~S119 (2005)
- Morino M, "Preoperative chemoembolization for hepatocellular carcinoma", J Surg Oncol Suppl, 3, pp.91~93 (1993)
- Jianyong L, "Preoperative adjuvant transarterial chemoembolization cannot improve the long term outcome of radical therapies for hepatocellular carcinoma", Sci Rep, 7, pp.41624~ (2017)
- Lopez-Lopez V, "Preoperative transarterial chemoembolization for laparoscopic liver resection in Child A cirrhotic patients with hepatocellular carcinoma", Langenbecks Arch Surg, 406, pp.763~771 (2021)
- Choi JH, "Prognostic effect of preoperative sequential transcatheter arterial chemoembolization and portal vein embolization for right hepatectomy in patients with solitary hepatocellular carcinoma", Korean J Hepatobiliary Pancreat Surg, 19, pp.59~65 (2015)
- Si T, "Preoperative transarterial chemoembolization for resectable hepatocellular carcinoma in Asia area : a metaanalysis of random controlled trials", Scand J Gastroenterol, 51, pp.1512~1519 (2016)
- Zhang Z, "The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma", Cancer, 89, pp.2606~2612 (2000)
- Monden M, "Significance of transcatheter chemoembolization combined with surgical resection for hepatocellular carcinomas", Cancer Chemother Pharmacol, 23(Suppl), pp.S90~S95 (1989)
- Wang X, "Influence of preoperative transarterial chemoembolization on the prognosis for patients with resectable hepatocellular carcinoma : a meta-analysis of randomized trials", Hepatogastroenterology, 58, pp.869~874 (2011)
- Lee KT, "The effect of preoperative transarterial chemoembolization of resectable hepatocellular carcinoma on clinical and economic outcomes", J Surg Oncol, 99, pp.343~350 (2009)
- Sasaki A, "Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma", Eur J Surg Oncol, 32, pp.773~779 (2006)
- Strasberg SM, "Nomenclature of hepatic anatomy and resections : a review of the Brisbane 2000 system", J Hepatobiliary Pancreat Surg, 12, pp.351~355 (2005)
- Dindo D, "Classification of surgical complications : a new proposal with evaluation in a cohort of 6336 patients and results of a survey", Ann Surg, 240, pp.205~213 (2004)
- Rahbari NN, "Posthepatectomy liver failure : a definition and grading by the International Study Group of Liver Surgery(ISGLS)", Surgery, 149, pp.713~724 (2011)
- Rahbari NN, "Posthepatectomy haemorrhage : a definition and grading by the International Study Group of Liver Surgery(ISGLS)", HPB(Oxford), 13, pp.528~535 (2011)
- Koch M, "Bile leakage after hepatobiliary and pancreatic surgery : a definition and grading of severity by the International Study Group of Liver Surgery", Surgery, 149, pp.680~688 (2011)
- Yamakado K, "Hepatic arterial embolization for unresectable hepatocellular carcinomas : do technical factors affect prognosis?", Jpn J Radiol, 30, pp.560~566 (2012)
- Yamakado K, "Subgrouping of intermediate-stage(BCLC stage B)hepatocellular carcinoma based on tumor number and size and Child-Pugh grade correlated with prognosis after transarterial chemoembolization", Jpn J Radiol, 32, pp.260~265 (2014)
- Yamakado K, "Prognosis of patients with intermediate-stage hepatocellular carcinomas based on the Child-Pugh score : subclassifying the intermediate stage(Barcelona Clinic Liver Cancer stage B)", Jpn J Radiol, 32, pp.644~649 (2014)
- Inchingolo R, "Locoregional treatments for hepatocellular carcinoma : current evidence and future directions", World J Gastroenterol, 25, pp.4614~4628 (2019)
- Higuchi T, "Hepatocellular carcinoma after transcatheter hepatic arterial embolization. A histopathologic study of 84 resected cases", Cancer, 73, pp.2259~2267 (1994)
- Wakasa K, "Effect of transcatheter arterial embolization on the boundary architecture of hepatocellular carcinoma", Cancer, 65, pp.913~919 (1990)
- Adachi E, "Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma. The relationship between postoperative course and tumor necrosis", Cancer, 72, pp.3593~3598 (1993)
- Kim BK, "Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma", J Hepatol, 62, pp.1304~1310 (2015)
- Yamashita Y, "Beneficial effects of preoperative lipiodolization for resectable large hepatocellular carcinoma(≥ 5 cm in diameter)", J Surg Oncol, 106, pp.498~503 (2012)
- Tustumi F, "Preoperative strategies to improve resectability for hepatocellular carcinoma : a systematic review and meta-analysis", HPB(Oxford), 20, pp.1109~1118 (2018)
- Zhang YF, "Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion : a prospective comparative study", Eur Radiol, 26, pp.2078~2088 (2016)
- Luo YQ, "Influence of preoperative transcatheter arterial chemoembolization on liver resection in patients with resectable hepatocellular carcinoma", Hepatobiliary Pancreat Dis Int, 1, pp.523~526 (2002)
- Kuroda C, "Limitation of transcatheter arterial chemoembolization using iodized oil for small hepatocellular carcinoma. A study in resected cases", Cancer, 67, pp.81~86 (1991)
- Goseki N, "Nourishment of hepatocellular carcinoma cells through the portal blood flow with and without transcatheter arterial embolization", Cancer, 76, pp.736~742 (1995)
- Ekelund L, "Blood supply of experimental liver tumors after intraarterial embolization with gelfoam powder and absolute ethanol", Cardiovasc Intervent Radiol, 7, pp.234~239 (1984)
- Yoshida K, "Isolated arteries originating from the intrahepatic arteries : anatomy, function, and importance in intervention", J Vasc Interv Radiol, 29, pp.531~537.e1 (2018)
- Sergio A, "Transcatheter arterial chemoembolization(TACE)in hepatocellular carcinoma(HCC) : the role of angiogenesis and invasiveness", Am J Gastroenterol, 103, pp.914~921 (2008)
- Wang B, "Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization", Acta Radiol, 49, pp.523~529 (2008)
- Miyayama S, "Portal blood supply to locally progressed hepatocellular carcinoma after transcatheter arterial chemoembolization : observation on CT during arterial portography", Hepatol Res, 41, pp.853~866 (2011)